Original language | English |
---|---|
Number of pages | 3 |
Journal | Journal of Clinical Oncology |
Volume | 39 |
Issue number | 15 |
DOIs | |
Publication status | Published - 20 May 2021 |
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER plus advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.
Komal L. Jhaveri, Elgene Lim, Erika P. Hamilton, Cristina Saura, Tarek Meniawy, Rinath Jeselsohn, J. Thaddeus Beck, Peter A. Kaufman, Sarah Sammons, Kalyan Banda, Meena Okera, Kan Yonemori, Kathleen Kiernan Harnden, Sung-Bae Kim, Joohyuk Sohn, Cynthia X. Ma, Philippe Georges Aftimos, Xuejing Aimee Wang, Suzanne R. L. Young, Muralidhar Beeram
Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review
26
Citations
(Web of Science)